BrightInsight is a Fierce Life Sciences Innovation Award Finalist

We are excited to share that BrightInsight is a finalist for the Fierce Life Sciences Innovation Awards 2021 in the Digital Health Solutions category. Entries were judged on effectiveness, technical innovation, competitive advantage, financial impact, and true innovation.

According to Fierce, the Digital Health Solutions category show cases forward thinking innovation and the best use of digital technology and mobile apps to better serve the industry.

The BrightInsight® Platform enables our global biopharma and medtech clients to build digital health solutions for use by clinical researchers, hospitals, healthcare providers, patients, and caregivers. These are regulated SaMD solutions across therapy areas – from dosing calculators, to dosing algorithms, to disease management solutions, to patient selection or therapy matching algorithms, and more. Therapy areas include diabetes, respiratory, oncology, ophthalmology, obesity, hematology, immunology, neurology, among others.

BrightInsight launched seven Software as a Medical Device (SaMD) solutions for our clients in the past 18 months, averaging around nine months’ time to market. We developed AMAZE, a chronic disease management platform. AstraZeneca and Mass General Hospital launched pilot programs of the AMAZE Chronic Disease Management platform built on the BrightInsight Platform, to help better connect healthcare providers and their patients with chronic conditions including COPD, asthma, chronic kidney disease and heart failure. We are Novo Nordisk’s global digital health partner and have multiple engagements with Novo Nordisk including managing the data from their next-generation connected insulin pens. The BrightInsight Platform captures data from Novo Nordisk’s next-generation connected insulin pens and integrate data from leading third-party diabetes solutions, including the Abbott Freestyle Libre system, the Glooko Diasend platform, Dexcom continuous blood glucose meters, as well as diabetes solutions from Roche. Novo’s non-exclusive partnership strategy is incredibly unique in an industry where data is historically very siloed. With Roche, we developed a dosing calculator for clinicians to use in treating patients with Hemophilia A in Europe. And we helped CSL Behring develop and launch a patient app for patients with rare and serious diseases.

We are honored to make it to the finalist list of this highly regarded annual award. This recognition confirms our team’s expertise and dedication to our mission of improving health care through the power of digital. Wish us luck! Winners will be announced in the Innovation Report on Monday, December 6.

Back to Blog